Roth Capital Downgrades Five Prime Therapeutics (FPRX) to Neutral, Following Acquisition
Tweet Send to a Friend
Roth Capital analyst Tony Butler downgraded Five Prime Therapeutics (NASDAQ: FPRX) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
